# 00 0(


## **Criteria for Value Assessment of Medication Adherence-Enhancing HTA193 Interventions: Preliminary Results of a Systematic Review** ISPOR MAP Special Interest Group\* **Special Interest**

### Introduction

- Medication non-adherence is prevalent across all clinical conditions and causes major medical and economic challenges.
- Medication Adherence-Enhancing Interventions (MAEIs) have demonstrated proven benefits in improving outcomes
- No systematic review of assessment of these interventions lacksquare
- Use of value frameworks in health technology assessment has been gaining popularity all around the world in the past decade
- Value framework for MAEIs could potentially improve the assessment by policy makers and other stakeholders, and ultimately could improve adherence

## **Objective**

## Figure 2. Distribution of Study Types (n=308)



Group

To systematically collect outcome measures used for the value assessment of MAEIs.

### **Methods**

- Search of MEDLINE and PsycINFO (via OVID), Scopus, and CINAHL and  $\bullet$ Academic Search Complete (via EBSCO).
  - Search years 2018-2020
- Study registered in PROSPERO (CRD42021242934) and conducted in accordance with PRISMA guidelines
- The screening was conducted in two steps:
  - Abstract and title screening of all identified records by two independent reviewers
  - Full text screening of potentially relevant articles by two independent Ο reviewers
  - Disagreements between reviewers were resolved by consensus Ο
- Exclusion criteria included
  - No abstract Ο
  - Article not reporting original data Ο
  - Not evaluating an MAEI, or not presenting a value framework for Ο pharmaceuticals or healthcare intervention programs
  - Not reporting relevant data Ο
- Data extracted included
  - General characteristics of the study (e.g., study type, study population, Ο country)
  - Data on MAEI

#### Table 1. Number of studies/outcome category

Outcome	N of studies (%)
Medication adherence/persistence	286 (93%)
Clinical outcome	155 (50%)
Quality of life	57 (19%)
Resource use	43 (14%)
Patient satisfaction	31 (10%)
Economic outcome	18 (6%)
Other outcome	76 (25%)


### Table 2. Type of MAEIs per intervention category

Type of MAEI	N of MAEIs (%)
Behavioral intervention	143 (44%)
Reminders (e.g., mail, telephone, email)	48 (35%)
Adherence monitoring with or without feedback	18 (13%)
Follow-up (e.g., home visit, scheduled clinic visit)	12 (8%)
Tailoring (routinization)	19 (7%)
Skill building (supervised, group)	8 (6%)
Multi-compartment pillbox/calendar pack/compliance aid	5 (3%)
Reminder chart/medication list	5 (3%)
Other	37 (26%)
Educational intervention	110 (34%)
Mixed behavioral & educational intervention	73 (22%)

- Data on value framework
- Relevant value domains and elements with a definition and measurement Ο method where available
- Data were categorized by type of outcome, type of intervention

#### Results

## Figure 2. PRISMA Flow Diagram



Discussion		
•	A variety of outcomes were used to assess MAEIs but many were	
	considered secondary outcomes of study	
	Limited studies reported on impact of MAEIs on economic outcomes	
	Behavioral interventions dominate MAEIs followed by educational	
	interventions. However, most of the behavioral interventions were also	

- interventions. However, most of the behavioral interventions were also reminder-based interventions
- Though mixed interventions are considered the most effective to improve medication adherence, only 22% of studies used them.
- Among the types of outcomes, medication adherence/persistence dominated followed by clinical outcomes
- Several relevant "other" type outcomes were identified. Further qualitative analyses may be needed to identify the relevance of these

outcomes

#### Conclusion

- There are many studies examining MAEIs, with nearly half behavioral interventions alone and only 22% using combined methods
- Further studies would be warranted to select and rank the most relevant outcome measures for the value assessment of MAEIs

\*Authors: Tamás Ágh; Mickaël Hiligsmann; Ivett Jakab; Charlotte Beaudart; Elizabeth Manias; Bijan J. Borah; Priti Pednekar; John Zeber; Adina Turcu-Stiolica, Christopher Daly; Chintal H. Shah; Shubham Atal; Manvi Sharma; Yingnan Zhao; Maria Dimitrova; Shweta Kamat; Gediwon Milky; David Hutchins; Nilesh Gangan; Elizabeth J Unni; Melania Brzozowska; Seyed Hossein Hajimiri; Manthan D. Janodia; Andrew M. Peterson